Evidence map›Paper›PMID 35664751›Full record

ArticleFrontiers in oncology2022

Risk Prediction of Second Primary Malignancies in Primary Early-Stage Ovarian Cancer Survivors: A SEER-Based National Population-Based Cohort Study.

Jiaqin Xu, Chen Huang, Zhenyu Wu, Huilin Xu, Jiong Li, Yuntao Chen, Ce Wang, Jingjing Zhu, Guoyou Qin, Xueying Zheng and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 15 citations in OpenAlex.

  1. Integrated Clinicogenomic Risk Modeling for Metachronous Second Primary Cancers.medRxiv : the preprint server for health sciences · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Jiaqin XuDepartment of Biostatistics, School of Public Health, Fudan University, Shanghai, China.
Chen HuangDepartment of Biostatistics, School of Public Health, Fudan University, Shanghai, China.
Zhenyu WuDepartment of Biostatistics, School of Public Health, Fudan University, Shanghai, China.
Huilin XuShanghai Minhang Center for Disease Control and Prevention, Shanghai, China.
Jiong LiDepartment of Clinical Epidemiology, Aarhus University, Aarhus, Denmark.
Yuntao ChenDepartment of Epidemiology and Public Health, University College London, London, United Kingdom.
Ce WangDepartment of Biostatistics, School of Public Health, Fudan University, Shanghai, China.
Jingjing ZhuDepartment of Biostatistics, School of Public Health, Fudan University, Shanghai, China.
Guoyou QinDepartment of Biostatistics, School of Public Health, Fudan University, Shanghai, China.
Xueying ZhengDepartment of Biostatistics, School of Public Health, Fudan University, Shanghai, China.
Yongfu YuDepartment of Biostatistics, School of Public Health, Fudan University, Shanghai, China.
Fudan University · CNAarhus University · DKShanghai Municipal Center For Disease Control Prevention · CNUniversity College London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: This study aimed to characterize the clinical features of early-stage ovarian cancer (OC) survivors with second primary malignancies (SPMs) and provided a prediction tool for individualized risk of developing SPMs. Methods: Data were obtained from the Surveillance, Epidemiology and End Results (SEER) database during 1998-2013. Considering non-SPM death as a competing event, the Fine and Gray model and the corresponding nomogram were used to identify the risk factors for SPMs and predict the SPM probabilities after the initial OC diagnosis. The decision curve analysis (DCA) was performed to evaluate the clinical utility of our proposed model. Results: A total of 14,314 qualified patients were enrolled. The diagnosis rate and the cumulative incidence of SPMs were 7.9% and 13.6% [95% confidence interval (CI) = 13.5% to 13.6%], respectively, during the median follow-up of 8.6 years. The multivariable competing risk analysis suggested that older age at initial cancer diagnosis, white race, epithelial histologic subtypes of OC (serous, endometrioid, mucinous, and Brenner tumor), number of lymph nodes examined (<12), and radiotherapy were significantly associated with an elevated SPM risk. The DCA revealed that the net benefit obtained by our proposed model was higher than the all-screening or no-screening scenarios within a wide range of risk thresholds (1% to 23%). Conclusion: The competing risk nomogram can be potentially helpful for assisting physicians in identifying patients with different risks of SPMs and scheduling risk-adapted clinical management. More comprehensive data on treatment regimens and patient characteristics may help improve the predictability of the risk model for SPMs.

Indexed as

competing risk modelnomogramovarian cancersecond primary malignanciesSEER database

Identifiers

PMID35664751
PMCPMC9161780
OpenAlexW4280603568

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.